<?xml version='1.0' encoding='utf-8'?>
<document id="27628584"><sentence text="Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects."><entity charOffset="20-29" id="DDI-PubMed.27628584.s1.e0" text="neratinib" /><entity charOffset="59-71" id="DDI-PubMed.27628584.s1.e1" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.27628584.s1.e0" e2="DDI-PubMed.27628584.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27628584.s1.e0" e2="DDI-PubMed.27628584.s1.e1" /></sentence><sentence text="To evaluate the effect of lansoprazole, a proton-pump inhibitor, on the absorption, pharmacokinetics, and safety of neratinib, a pan-HER tyrosine kinase inhibitor, in healthy subjects"><entity charOffset="26-38" id="DDI-PubMed.27628584.s2.e0" text="lansoprazole" /><entity charOffset="116-125" id="DDI-PubMed.27628584.s2.e1" text="neratinib" /><entity charOffset="137-145" id="DDI-PubMed.27628584.s2.e2" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.27628584.s2.e0" e2="DDI-PubMed.27628584.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27628584.s2.e0" e2="DDI-PubMed.27628584.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27628584.s2.e0" e2="DDI-PubMed.27628584.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27628584.s2.e1" e2="DDI-PubMed.27628584.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27628584.s2.e1" e2="DDI-PubMed.27628584.s2.e2" /></sentence><sentence text="" /><sentence text="This was an open-label, two-period, fixed-sequence study" /><sentence text=" Fifteen healthy adult subjects received a single oral dose of neratinib 240 mg (Period 1), followed by a washout period, then oral lansoprazole 30 mg once daily for 7 days and a single dose of neratinib 240 mg on Day 5 (Period 2)"><entity charOffset="63-72" id="DDI-PubMed.27628584.s5.e0" text="neratinib" /><entity charOffset="132-144" id="DDI-PubMed.27628584.s5.e1" text="lansoprazole" /><entity charOffset="194-203" id="DDI-PubMed.27628584.s5.e2" text="neratinib" /><pair ddi="false" e1="DDI-PubMed.27628584.s5.e0" e2="DDI-PubMed.27628584.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27628584.s5.e0" e2="DDI-PubMed.27628584.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27628584.s5.e0" e2="DDI-PubMed.27628584.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27628584.s5.e1" e2="DDI-PubMed.27628584.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27628584.s5.e1" e2="DDI-PubMed.27628584.s5.e2" /></sentence><sentence text=" Pharmacokinetic sampling was performed for 72 h following each neratinib dose"><entity charOffset="64-73" id="DDI-PubMed.27628584.s6.e0" text="neratinib" /></sentence><sentence text=" Plasma neratinib concentration-time data were analysed using noncompartmental methods"><entity charOffset="8-17" id="DDI-PubMed.27628584.s7.e0" text="neratinib" /></sentence><sentence text=" Geometric mean ratios for AUC0-t , AUC0-inf , and peak plasma concentrations (Cmax ) for neratinib plus lansoprazole vs"><entity charOffset="90-99" id="DDI-PubMed.27628584.s8.e0" text="neratinib" /></sentence><sentence text=" neratinib were used to assess the magnitude of the drug-drug interaction if the 90% confidence intervals were outside 80"><entity charOffset="1-10" id="DDI-PubMed.27628584.s9.e0" text="neratinib" /></sentence><sentence text="00-125" /><sentence text="00%" /><sentence text="" /><sentence text="Neratinib geometric least-squares mean (LSM) Cmax was reduced from 84"><entity charOffset="0-9" id="DDI-PubMed.27628584.s13.e0" text="Neratinib" /></sentence><sentence text="5 ng ml-1 with neratinib alone to 24"><entity charOffset="15-24" id="DDI-PubMed.27628584.s14.e0" text="neratinib" /></sentence><sentence text="5 ng ml-1 with neratinib plus lansoprazole"><entity charOffset="15-24" id="DDI-PubMed.27628584.s15.e0" text="neratinib" /><entity charOffset="30-42" id="DDI-PubMed.27628584.s15.e1" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.27628584.s15.e0" e2="DDI-PubMed.27628584.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27628584.s15.e0" e2="DDI-PubMed.27628584.s15.e1" /></sentence><sentence text=" The extent of exposure to neratinib was also decreased: geometric LSM AUC0-t was 1478 ng ml-1  h with neratinib vs"><entity charOffset="27-36" id="DDI-PubMed.27628584.s16.e0" text="neratinib" /><entity charOffset="103-112" id="DDI-PubMed.27628584.s16.e1" text="neratinib" /><pair ddi="false" e1="DDI-PubMed.27628584.s16.e0" e2="DDI-PubMed.27628584.s16.e0" /><pair ddi="false" e1="DDI-PubMed.27628584.s16.e0" e2="DDI-PubMed.27628584.s16.e1" /></sentence><sentence text=" 426 ng ml-1  h with neratinib plus lansoprazole, and geometric LSM AUC0-inf was 1557 ng ml-1  h vs"><entity charOffset="21-30" id="DDI-PubMed.27628584.s17.e0" text="neratinib" /><entity charOffset="36-48" id="DDI-PubMed.27628584.s17.e1" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.27628584.s17.e0" e2="DDI-PubMed.27628584.s17.e0" /><pair ddi="false" e1="DDI-PubMed.27628584.s17.e0" e2="DDI-PubMed.27628584.s17.e1" /></sentence><sentence text=" 542 ng ml-1  h, respectively" /><sentence text=" Mean t½ was similar with both treatments (approximately 14 h)" /><sentence text=" Geometric mean ratios 90% confidence intervals for AUC0-t , AUC0-inf and Cmax fell outside the prespecified equivalence range (80" /><sentence text="0-125" /><sentence text="0%)" /><sentence text=" Treatment-emergent adverse events, all mild, were reported by five (33%) subjects" /><sentence text="" /><sentence text="Coadministration of lansoprazole with neratinib reduced the rate and extent of neratinib exposure in healthy subjects"><entity charOffset="20-32" id="DDI-PubMed.27628584.s25.e0" text="lansoprazole" /><entity charOffset="38-47" id="DDI-PubMed.27628584.s25.e1" text="neratinib" /><entity charOffset="79-88" id="DDI-PubMed.27628584.s25.e2" text="neratinib" /><pair ddi="false" e1="DDI-PubMed.27628584.s25.e0" e2="DDI-PubMed.27628584.s25.e0" /><pair ddi="false" e1="DDI-PubMed.27628584.s25.e0" e2="DDI-PubMed.27628584.s25.e1" /><pair ddi="false" e1="DDI-PubMed.27628584.s25.e0" e2="DDI-PubMed.27628584.s25.e2" /><pair ddi="false" e1="DDI-PubMed.27628584.s25.e1" e2="DDI-PubMed.27628584.s25.e1" /><pair ddi="false" e1="DDI-PubMed.27628584.s25.e1" e2="DDI-PubMed.27628584.s25.e2" /></sentence><sentence text="" /></document>